Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

Not Applicable

Recruiting

• Conditions: Healthy Participants
• Interventions: Drug: Allisartan Isoproxil Tablets 240mg or placebo; Drug: Allisartan Isoproxil Tablets 480mg or placebo; Drug: Allisartan Isoproxil Tablets 720mg or placebo

• Registration Number: NCT07174830
• Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Brief Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy Chinese subjects at single dose administration of Allisartan Isoproxil Tablets (240 mg ,480 mg or 720 mg）or placebo. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of Allisartan Isoproxil Tablets.

Detailed Description

This study will be conducted at 1 study center in Shenzhen. 18 healthy Chinese male and female participants per group, aged 18 to 65 inclusive, will be randomized in a 5:1 ratio to receive a single administration of Allisartan Isoproxil Tablets (240 mg ,480 mg or 720 mg）or placebo (54 participants in total). Each participant will participate in only 1 treatment group. Blood samples will be collected up to 72 hours post-dose for pharmacokinetic parameter calculation, and safety monitoring will continue until sample collection is complete.

Study Timeline

• Status Verified: 2025-09
• Study Start: 2025-09-06
• Study First Submitted: 2025-09-06
• Study First Submitted QC: 2025-09-15
• Last Update Submitted: 2025-09-15
• Study First Posted: 2025-09-16
• Last Update Posted: 2025-09-16
• Primary Completion: 2025-12-31
• Study Completion: 2026-02-16

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• Healthy male or female adults aged 18 to 65 years (inclusive).
• Body weight ≥50 kg for male participants and ≥45 kg for female participants at screening, with a body mass index (BMI) between 19.0 and 25.0 kg/m2.
• Seated systolic blood pressure (SBP) ≥100 mmHg and <140 mmHg, seated diastolic blood pressure (DBP) ≥70 mmHg and <90 mmHg, and no orthostatic hypotension at screening.
• Participants must be able to communicate effectively with the investigator, fully understand the trial's objectives and requirements, voluntarily participate in the clinical trial, and provide written informed consent.

Exclusion Criteria

• Known or suspected allergy to Allisartan Isoproxil, , other ARBs, or any excipients of this formulation.
• Abnormal findings in physical examination, vital signs, electrocardiogram (ECG), or laboratory tests that are clinically significant as judged by the investigator.
• Any medical history or current condition that may impact participant safety assessments or the pharmacokinetics of the investigational drug, including but not limited to disorders of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematologic system, immune system, psychiatric conditions, metabolic abnormalities, or prior gastrointestinal surgery.
• Used any prescription drugs, over-the-counter medications,Chinese herbal medicines, or food supplements within 14 days prior to screening.
• Participants with hyponatremia, hyperkalemia, or hypovolemia;
• Participants with a history of orthostatic hypotension or syncope;
• Participants who have received any vaccinations within 4 weeks prior to screening.
• Participants who consume excessive amounts of strong tea, coffee, and/or caffeinated beverages (≥8 cups/day, 1 cup=250 mL), or have consumed such beverages within 48 hours prior to dosing, or cannot abstain during the trial;
• Participants with habitual intake of xanthine-rich or grapefruit-containing products, or have consumed such products within 48 hours prior to dosing, or cannot abstain during the trial;
• Female participants who are pregnant or breastfeeding;
• Participants (or their partners/spouses) who plan pregnancy, sperm/egg donation, or refuse to use at least one acceptable contraceptive method during the trial and for 3 months post-study ;
• Participants with a positive result for any of the following tests: hepatitis B surface antigen test, hepatitis C antibody test, HIV antibody test, and treponema pallidum antibody test.
• Heavy smokers or Participants with an average tobacco consumption of more than 5 cigarettes per day within 3 months prior to screening, or those who could not completely stop consuming tobacco products during the study.;
• Heavy drinkers or Participants with an average alcohol consumption of more than 14 units per week (1 unit=360 mL beer/45 mL 40% spirits/150 mL wine) within 3 months prior to screening, or with a positive result for breath alcohol test at screening, or those who could not completely stop consuming alcohol-containing food or beverages during the study;
• Participants with a positive result for drug abuse test at screening, or a history of drug abuse(past 5 years), or recent illicit drug use (within 3 months prior to screening);
• Participants who have participated in other drug/device trials and received investigational products within 3 months prior to screening;
• Participants who have donated blood (≥400 mL), received transfusions, or used blood products within 3 months prior to screening;
• Participants with difficult venous access or intolerance to repeated venipuncture;
• Participants with difficulty swallowing study medication; Participants deemed by investigators to have poor compliance or other factors unsuitable for trial participation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Allisartan Isoproxil Tablets 240mg	Allisartan Isoproxil Tablets 240mg or placebo	Allisartan Isoproxil Tablets 240mg, QD
Allisartan Isoproxil Tablets 480mg	Allisartan Isoproxil Tablets 480mg or placebo	Allisartan Isoproxil Tablets 480mg, QD
Allisartan Isoproxil Tablets 720mg	Allisartan Isoproxil Tablets 720mg or placebo	Allisartan Isoproxil Tablets 720mg, QD

Primary Outcome Measures

Name	Time	Method
Incidence of treatment-emergent adverse events	up to Day 4	Incidence of treatment-emergent adverse events during the whole study
Cmax	Day 1 to Day 4	Observed maximum plasma concentration (Cmax)
AUC0-t	Day 1 to Day 4	Plasma concentration-time curve from time zero extrapolated to the time of last quantifiable concentration (AUC0-t)

Trial Locations

Locations (1)

Shenzhen People's Hospital; 🇨🇳 Shenzhen, Guangdong, China